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Anti-phosphocholine (PC) 1 antibodies raised in the serum response to PC-antigens 
segregate into  three  main  families on  the  basis  of differential  recognition  by anti- 
idiotypic (Id) antibodies. One family shares public Id determinants found on a group 
of nearby identical  PC-binding  myeloma proteins  (MP),  e.g.,  TEPC  15,  HOPC 8, 
S107.  Another  family possesses public  determinants  common to two other anti-PC 
MP,  MOPC  511  and  MOPC  167,  whereas  the  third  contains  public  Id shared  by 
another  two  anti-PC  MP,  McPC  603  and  W3207  (1-4).  Recent  studies  (5)  on 
hybridoma proteins (HP) generated from six different strains of mice immunized with 
two  different  PC-antigens,  Streptococcus  pneurnoniae  (R36A)  and  PC-protein,  have 
confirmed the presence of these three families and their dominance in  the immune 
response.  Structural  and  biochemical studies  on hybridoma antibodies  have shown 
that each of the three families uses a  distinct  V  region for its L  chain  (1, 6). 2 The L 
chains in the T15 family belong to the VK-22 isotype, those in the M511  family use 
VK-24 L chains, and those in the M603  family are VK-8 L  chains.  By contrast, the 
VH  all  fall  into  the  same V  region  isotype, VH-4.  Thus,  these  liP  families show 
conservation that parallels that seen in serum anti-PC antibody families (7, 8). 
In  spite  of this  observed  structural  similarity,  idiotypic  and  isoelectric  focusing 
studies revealed heterogeneity within a family (2-4, 9, 10). Our initial experiments on 
HP  (5)  suggested that some of the structural  heterogeneity occurred in  the binding 
site. To evaluate the functional significance of this heterogeneity, we performed more 
detailed studies on the binding activity of the HP using three different PC-antigens 
(carrier  effects)  and  a  variety of choline  (C)  analogues  (hapten  effects).  We  have 
confirmed our previous observations that each family can be distinguished  from the 
others.  In addition,  we have detected  binding-site  heterogeneity  for hapten  within 
members of the M511  and M603 families but not among members of the T15 family, 
even though the latter are derived from several strains and have known VH and VL 
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differences. A  third observation is the existence of differential reactivity for carrier 
determinants  among  HP  and  MP  that  exhibit  indistinguishable  hapten-binding 
profiles. These results are discussed in  terms  of structure-function  relationships and 
the biological importance of functional heterogeneity within antibody families arising 
in the same response. 
Materials  and  Methods 
Myeloma andHybridoma Proteins.  The PC-BMP, T15, H8, M603, W3207, M511, and M167 
were purified from ascites fluid by affinity chromatography on  PC-Sepharose, as previously 
described (1). Anti-PC HP were generated by cell fusion with the nonseereting cell lines SP2/ 
0-Agl4 (11)  (fusion numbers _<116) or X63-Ag8.653 (12)  (fusion numbers ~120).  Spleen cells 
were obtained from mice immunized with  l0  s Streptococcus pneumoniae (R36A)  (fusion numbers 
"::120) or with  100-200 #g PC-keyhole limpet hemocyanin or bovine gamma globulin (BGG) 
(fusion number ~130 and  116), as previously described (5). Anti-PC hybridomas were propa- 
gated in Iseove's hypoxanthine-aminopterin-thymidine, subcioned in soft agar over thymocyte 
feeder layers (13),  and stored frozen. Selected hybridomas were grown in ascites in pristane- 
primed H-2-compatible or irradiated mice. The anti-PC HP were purified by affinity chro- 
matography, as described above. All HP were found to contain a  single molecular species as 
judged by sodium dodeeyl sulfate-polyacrylamide  gel electrophoresis (SDS-PAGE) and isoelec- 
tric focusing (IEF) in polyacrylamide  gels (1). HP are designated by a three-component number 
m.n.o., where m  refers to the fusion number, n refers to the clone number, and o refers to the 
subelone number. 
Haptens and PC-Antigens.  PC and  L-a-glycerophosphocholine (GPC)  were purchased from 
Sigma Chemical Co., St. Louis, Mo. 3-(p-azophenylphosphocholine)-N-aeetyl-L-tyrosylglycyl- 
glycine (YGG) Boc hydrazide (PC-Y) was purchased from Bioseareh, San Rafael, Calif. All the 
remaining haptens  were synthesized from  commercial precursors, using C,  H,  N  elemental 
analysis as the criterion of purity. These compounds have been described previously (14), and 
they are all listed in Table I. PC-BGG was prepared as previously described (2). Soluble PC- 
containing antigens were prepared from extracts of R36A and Proteus morganii (Potter) (15, 4). 
Briefly, washed R36A bacterial cells at concentrations _>10S/ml were heated at 60°C for 30-40 
min. After centrifugation at 5,000 g, the cell-free lysate was precipitated three times with 80% 
ethanol  in water and  then  dissolved in phosphate-buffered saline containing 0.04%  sodium 
azide  (PBS-A). Washed P. morganii cells were  extracted with  0.05%  SDS, 0.015  M  sodium 
citrate, and  0.15  M  NaC1  at  56°C  for 60  min.  The  cell-free supernatant  was  exhaustively 
dialyzed against PBS-A. These antigens still contained protein complexed with the PC-antigen 
that made possible radiolabeling  with iodine. Both the R36A and P. morganii  extracts contained 
C  (4) and gave strong precipitin reactions with T15 and M603, respectively. 
Antigen-binding of Anti-PC Hybridoma Antibodies.  The binding pattern of each HP for the C 
analogues listed in Table I was assessed in a competitive solid-phase radioimmunoassay (SRIA). 
A comparison was made of the molar concentration of the C analogues required to inhibit the 
reaction between antibody-coated plates and  125I-labeled  PC-BGG  (5),  R36A, or P. morganii 
extracts. The relative binding efficiency was expressed as the ratio of the molar concentration 
of C  analogue giving 50%  inhibition (I~0) to the molar concentration of PC  at  I50. A  stock 
solution at 0.1  M  was made for each analogue in PBS, pH 7.4, and used for all experiments. 
This proved a useful and reproducible assay for accurately measuring and comparing hapten- 
binding activities of anti-PC antibodies. 
The ability of each anti-PC antibody to bind PC attached to different carriers was measured 
in direct titration SRIA. Briefly, dilutions (100-0.1 #g/ml) of each HP and MP were used to 
coat duplicate wells in polyvinylchloride microtiter plates (Dynatech Laboratories, Inc., Alex- 
andria, Va.). After overnight incubation, washing with PBS-A, and brief incubation in PBS-A 
containing 1% BSA, 10,000 cpm of radioiodinated PC-BGG, R36A, or P. morganii  extracts were 
added,  with  one  antigen  for each  set  of dilutions. Maximum  binding was  taken  from  the 
plateau portion of the curve that occurred between  100 to 10 #g/ml. 1586  ANTI-PHOSPHOCHOLINE  BINDING  SITES 
TABLE  I 
Hapten Analogues 
Figure symbol,  Structure 
Compound  abbreviation 
Phosphocholine  ~  ---I, PC 
O 
II 
(C  H,)  ~--N ÷---CH2~-C H2--,O -- p--OH 
I 
O 
3-Phosphopropyl  TMA*  O-----O, PPTMA 
3-(p-azophenyl  PC)-N-acetyl-YGG  ~-'-O,  PC-Y 
Boc hydrazide 
3-Carboxypropyl  TMA$  O-'--'O, 3COOH 
4-Carboxybutyl  TMA§  *--*,  4COOH 
5-Carboxypentyl  TMA§  O-'---O, 5COOH 
3-Phenylpropy]  TMA§  0-----0, 3 
4-Phenylbutyl  TMA§  *-----*, 4 ~, 
5-Phenylpentyl  TMA§  O- -'O, 5 ck 
o-Choline sulfate  l--.--~  OCS 
O 
IL 
(C H 3)  3--N+---C H2--CH2---C H 2---O  -- p ---OH 
I 
O- 
O 
(CH~)  3--N +---C  H 2---CH2---O  -- ! --O  -'- ~--N=N-- 
O- 
YGG Boc hydrazide 
O 
II 
(C  H3) a--N+---C H2--..-C  H f.--  CH~-- C --O  - 
O 
tl 
(C  H 3)  s--N  +'--'C  H ~"""C  H 2""-C  H 2---C  H 2  -"-C --O 
O 
(C H a)  a--  N +  ---C H ~-.--C  H 2---C  H 2-.-C  H 2-..~ H ~-......C  ---O 
(C Ha)  a--N+--C H2-"CH2--"CH2-- 
(CH3)  a--N +'--CH2"-C  H f"-CH  2--'CH 2-- ~ 
(CHa)  a--N+-"CH2-"C  H~'C H2-"C  H2-"C  H2-- 
O 
II 
(CH  s)  a--N+--CH 2---CH2---O  -- S --O 
II 
O 
2-(TMA)  Ethanesulfonic  acid  TES 
O 
II 
(CH  3)  3--N+----CH  f--C H2  -  S--O 
II 
O 
* TMA =  trimethylammonlum. 
$ Iodide salt. 
§ Bromide salts. 
Results 
Anti-PC  Antibodies.  Table  II  summarizes  the  origin  and  characteristics  of  the 
monoelonal  anti-PC  antibodies  used  in this study.  Many of these  MP  and  HP  have 
been  described  previously  (5).  All  the MP are IgA and arose in BALB/c  or CBB22, 
a  BALB/c  congenic  strain  carrying  the  C57BL  allotype  at  the  Igh  locus.  The  HP ANDRES  ET AL. 
TABLE II 
Anti-PC Hybridoma  and Myeloma  Proteins 
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HP or MP  Mouse strain  Igh  Ig Class 
12hi-labeled antigen* 
PC-BGG  S. pneumoniae  P. morganii 
The T15 Family 
T15  BALB/c  a  IgA  4,220  1,090  220 
H8  BALB/e  a  IgA  4,068  980  400 
134.5Bll  BALB.G  a  IgGa  5,130  1,011]]  193[[ 
59.6C5.1  BAB14  a/b  IgG3  5,420  1,110  1,750 
C3  CBB22  b  IgA  4,690  830  80 
22.1A45  AKR  d  IgM  4,780  680  280 
101.8E4.4  CBA  j  IgM  4,660  890  300 
140.7C6.2  CBA  j  IgM  5,060  1,000  350 
100.6G2.1  CBA  j  IgG2  5,050  1,140  1,530 
140.3D9.2§,. 1C2.2  CBA  j  IgG2  5,180  1,030  2,650 
103.1 C9.1  :]:  PL  j  IgG2  5,320  1,200  1,550 
The M511/M 167 Family 
M511  BALB/c  a  IgA  4,490  460  0 
M 167  BALB/c  a  IgA  5,100  640  0 
137.2D3  C57L  a  IgM  ND¶  ND  ND 
137.7C9.1  §, .5G6.1  C57L  a  IgG1  2,300  160  0 
100.1C 11.5  CBA  j  IgM  3,250  330  0 
101.3C2.2  CBA  j  IgM  4,100  410  0 
101.6G6.2,§.3G8.4,  CBA  j  IgM  4,830  190  150 
.6E5.1 ,.6F6.4 
120.2E5.2  CBA  j  IgM  ND  400  0 
The M603 Family 
M603  BALB/c  a  IgA  2,950  490  3,350 
W3207  BALB/c  a  IgA  3,580  530  500 
55.6F3.4,. 7C8.4§  BALB/c  a  IgM  3,210  300  480 
116.5F3.2  BALB.G  a  IgGl  4,540  230  0 
131.3B8  BALB.G  a  IgGa  ND  ND  ND 
137.6F2.1  C57L  a  IgG2  ND  ND  ND 
100.6F9.1,.6G2.2§  CBA  j  IgM  3,780  550  3,270 
* Cpm of antigen bound by antibody-coated wells. Antibody concentrations of 10 pg/ml (vs. PG-BGG) or 
100 #g/ml (vs. S. pneumoniae or P  morganii) were used to coat duplicate wells. 10,000 cpm of radiolabeled 
antigen were added to each well. 
:]: Carries Igk-PC-A marker; all other HP in this family are Igk-PC-B. 
§ HP on the same line arose in the same fusion and were identical by idiotype and binding studies. Results 
of antigen binding are reported for the first HP listed; all others in the group were similar. 
[I Results obtained with 10 p.g/ml of antibody. 
¶ Not done. 
represent  all  the  major  serum  isotypes  except  IgA  and  come  from  seven  different 
strains.  Idiotyping  of  HP  consistently  yielded  the  three  major  groups  or  families 
shown, regardless of strain. IEF of isolated L  chains showed that within a  family, the 
L  chains co-isofocused  (except  for HP116.5F3.2,  which has been tentatively assigned 
to the  M603  family, and for electrophoretic  shifts resulting from  genetic markers  in 
the T15 family) (5). Sequence analysis of the MP has shown that the L  chains within 
a  family are either identical or strikingly similar, but between families they belong to 
three  different VK  isotypes  (16,  17).  Sequence analysis of representative HP  reveals 
exactly the same pattern  (6). 2 Thus, in this  instance there  is an absolute correlation 1588  ANTI-PHOSPHOCHOLINE BINDING SITES 
between an IEF pattern and a VK isotype. The H chains of all the MP and HP so far 
sequenced belong to the VH-4 isotype. 
In published and unpublished studies, we and others have been able to subdivide 
members  of  family  idiotypically.  For  example,  T15,  C3,  HP103.1C9.1,  and 
HP140.1C2.2 can be distinguished from each other by private anti-idiotypic antisera 
(18,  19).  Similar  findings  have  been  made  for  M511,  M167,  HP101.3C2.2, 
HP137.5G6.1, and HP101.6G6.2 in the M511/M167  family (20, 21) and for M603, 
W3207, HP55.6F3.4, HP116.5F3.2, and HP100.6F9.1 in the M603 family (S. Hudak, 
and  L.  Claflin,  unpublished  data).  The  bases  for  these  idiotypie  differences  are 
currently unknown, but they do provide direct evidence for structural diversity within 
a family. 
Binding Site Specificity: Carrier Effects.  Anti-PC antibodies were first tested for their 
ability  to bind  three different  PC-antigens,  PC-BGG, and  the  two  polysaccharide 
antigens isolated from S. pneumoniae and P. morganii. The results compiled from four 
experiments are summarized in Table II. All MP and HP bound the hapten-protein 
conjugate about equally well even though most of the HP were derived from R36A 
immunized mice, i.e., fusion number ___120, except  116. The binding to R36A was 
more  variable,  particularly  within  the  M511  and  M603  families.  The  T15  HP 
consistently bound more of this antigen than did HP of the M511  or M603 families. 
No correlation was observed between carrier specificity and antigen used to prime the 
spleen cell donor. Binding to P. morganii occurred only among T15 and M603 HP and 
MP.  Some of these antibodies  bound P.  morganii well  (1,530-3,350  cpm),  whereas 
others reacted poorly (80-500 cpm). One M603  HP, HP116.5F3.2, did not bind P. 
morganii at all. No strain or Ig class effects were seen except among the T15 family, 
where IgA or IgM HP were all weak binders and the IgG were much stronger binders. 
This was not related to the polymeric nature of the antibody because some strongly 
binding IgM and IgA HP were observed among M603 HP. 
Binding  Site  Specificity:  Hapten  Effects.  To  obtain  additional  information  about 
binding site diversity, the binding reactivity of each anti-PC antibody was measured 
for a large number of analogues of C. These analogues were all derivatives of C (Table 
I)  in  the  form  (CH3)3N+(CH2)n-R.  They  all  contained  an  unmodified,  positively 
charged trimethylammonium group that is essential for binding (22)  and a charged 
or uncharged R  group at various distances from the quaternary nitrogen. This length 
variation was accomplished with  -CH2-residues.  The substituents originally tested 
were  phenyl,  hydroxyl,  and  carboxylate,  in  addition  to  phosphate,  sulfate,  and 
sulfonate. The results obtained with the hydroxyl series and the compounds in which 
the distal substituents were either very close together or far apart  are not reported 
because they gave negligible inhibition with all HP. The inhibition results obtained 
with more informative C analogues and representative members of all three antibody 
families are depicted in Figs.  1-3. A comparison of the inhibitory capacity relative to 
PC is tabulated in Fig. 4. 
Nonspecific effects of the C  analogues on protein interactions can be discounted 
because of the range of activity the analogues showed with different antibodies. In an 
independent control, the C analogues at 0.001 M  were unable to inhibit >20% of the 
binding of a monoclonal anti-TNP antibody to TNP-BGG. 
The T15 Family.  The fine specificity of all the T15 proteins listed in Table II were 
examined. Representative examples are shown in Fig.  1. The MP and HP presented ANDRES  ET  AL.  1589 
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FIG.  1.  Binding  site  profiles  at  anti-PC  HP  in  the  T15  family.  Binding  was  measured  in  a 
competitive  RIA  between  HP  and  125I-PC-BGG  (left  panels)  or  1~5I-S. pneumoniae polysaccharide 
(right panels).  Inhibitors and symbols are listed in Table  I. 
are indicative of the types of diversity that exist among the T15 HP. These consist of 
the  following:  (a)  CH  isotype:  included  are  two  or  more  proteins  of each  of the 
following classes:  IgA, IgG2b, IgGs, and IgM.  (b)  CH allotype:  the proteins arose in 
mice with  these Igh allotypes:  a, b, a/b,  d, and j.  (c)  VK polymorphism:  the T15  L 
chains have the isofocusing phenotype  of Igk-PC-A or Igk-PC-B.  (d)  Idiotype:  anti- 
idiotypic  sera made against  selected  HP react  with the T15  family of antibodies  in 
groups according to individual, allotype, and family specificities  (A. Maddalena  and 
J. L. Claflin,  unpublished observations).  (e)  Sequence:  among the MP, VH substitu- 
tions are known. In the D  region, HOPC8 is GLNgs, whereas T15 is SER99 (16); T15 
is  PRO14,  GLYa6,  PRO4o,  ARG44,  ALAa08,  whereas  C3  is  SER,  ARG,  ALA,  GLY, 
THR,  respectively  (17).  In  addition,  the  donors  for  fusions  were  immunized  with 
R36A or PC-protein. 
Among all  the  MP  and  HP of this  family,  the  fine specificities  are as similar  as 1590  ANTI-PHOSPHOCHOLINE  BINDING  SITES 
replicate  trials of one protein  (Fig.  4). Whether  the competing antigen  was PC-BGG 
(Fig.  1, left panel, 4) or R36A (Fig.  1, right panel, 4), the characteristic binding order 
of the  analogues  is  PC  >  PC-Y >>  5(/, ~  3COOH  ~  3~  ~  4COOH  >  3PPTMA. 
Those  HP  that  can  bind P.  morganii do so with  the same  fine specificity  with which 
they bind the other two antigens  (data not shown). 
M603  Family.  The  nine  M603  MP  and  HP  were  derived  from  four  different 
strains,  one of which  was congenic  to BALB/c.  They belonged  to all  the major CH 
isotypes.  All  the M603  MP  and HP  except  one exhibited  the same binding  pattern 
for the C haptens, PC >  PC-Y  --  3COOH >> 4COOH  =  OCS ~  3PPTMA >  5(/). A 
typical  result  is  shown  in  Fig.  2.  Repetition  of the  experiment  on  three  separate 
occasions did not reveal any significant  differences among these antibodies  (Fig. 4). 
Of particular interest are the findings that:  (a)  the inhibition profiles for M603  and 
HP100.6F9,  which  bind  P.  morganii, and W3207  and  HP55.7C8,  which  do not  bind 
this  antigen  well  are indistinguishable;  and  (b)  The antibodies  were the same when 
they were tested with either  PC-BGG  or P. morganii (Figs.  2  and 4). The exceptional 
pattern  was  seen  with  HPl16.5F3,  whose  molar  ratios  (vs.  PC)  at  I~o were  PC-Y, 
0.0022;  3PPTMA,  0.69;  4COOH,  0.83;  PC,  1;  3COOH,  1.7;  5~,  3.3;  and OCS,  17. 
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This antibody was  derived from a  PC-protein-immunized animal  and  showed  the 
strongest  binding  with  the  analogue  closest  in  structure  to  the  hapten  on  the 
immunizing antigen,  PC-Y.  By contrast, HP137.6F2.1, which also arose in a  C57L 
mouse injected with  PC-protein, possessed a  binding pattern  identical to the other 
HP. All HP and MP, except HP116.5F3, had L chains that co-focused with M603. 
No correlation of structure and  fine specificity was observed. For instance,  W3207 
and M603 exhibit differences in H  chain CDR 2 and 3 and some differences in their 
L  chains  (16,  23),  but  this  is  not  reflected in  their  binding  preference for  the  C 
analogues. 
The M511 Family.  The inhibition profiles obtained with these HP contrast sharply 
with those in the T15 and M603 families (Figs. 3 and 4), even though they came from 
the same strains of mice. No two patterns are the same unless the HP came from the 
same fusion, e.g.,  101,  137. One group of four HP from fusion  101,  prototyped by 
HP101.6G6.2, all exhibited the same inhibition pattern  (A  and •  in Fig.  4).  They 
also  share  private  idiotypes  (21).  The  two  BALB/c  MP  M511  and  M167,  whose 
structures are similar but not identical, can be readily distinguished from each other. 
Of particular interest is the finding that one BALB/c antibody (MS 1 I) and one CBA 
antibody (HP100.1C 11.5)  have quite similar binding orders for the C  analogues  ('k 
and "A" in Fig. 4). 
For all M511  HP and MP, PC and PC-Y were consistently excellent inhibitors. In 
the carboxylate series  (CHa)aN+(CH2)nCOO -,  the  inhibitory activity tended  to in- 
crease as n decreased to 3, although for one HP, HP101.3C2.2, the 4COOH hapten 
was  the best  inhibitor.  The n=3  carboxylate compound compares in size with  PC. 
Substitution of a phenyl group for the negatively charged phosphate or carboxylate 
group led to variable results. With four of the six antibodies, the phenyl series failed 
to give significant inhibition;  M511  and HP100.1CI 1.5, however, showed excellent 
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reactivity  with  the  n=5  compound.  Each  antibody  showed  a  unique  pattern  of 
reactivity with OCS and 3PPTMA. 
Discussion 
Multiple approaches  have been used to examine diversification  processes of anti- 
bodies having the same specificity. These include idiotypy, model building, measure- 
ment of binding activity, and complete amino acid sequencing. We have emphasized 
the  latter  two  approaches  becasuse  we  are  primarily  interested  in  how  structural 
differences  translate  into  functional  diversity.  Idiotypic  studies,  for example,  have 
aided in measuring the extent of structural diversity, but it does not necessarily follow 
that a structural change leads to a new binding site. Structural differences are already 
known to exist  among anti-PC  MP  and HP  and additional ones are  inferred  from 
IEF studies and the presence of private idiotypes (18-21). To understand the signifi- 
cance  of this  heterogeneity,  especially  within  a  family,  we  attempted  to  obtain  a 
"fingerprint" of the binding site both in its reactivity for hapten and for hapten plus 
carrier.  For the former,  we used hapten inhibition of binding to ligand, in this case 
PC  linked  to  three  different  carriers.  Leon  and  Young  (24)  successfully  used  this 
approach first to recognize the specificity of the anti-PC MP and to identify function- 
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to identify one group of antibodies in a much larger population (25) or to subdivide 
HP having a  particular specificity into distinct functional groups (26, 27). To assess 
carrier effects, we  have tested the ability of each  MP or HP  to bind  the  artificial 
antigen PC-BGG and two natural PC-antigens, S. pneumoniae and P. morganii. In each 
instance the haptenic moiety is constant. However, the linkages as well as the adjacent 
carrier determinants are quite different. In  PC-protein conjugates,  PC  is  phospho- 
diester linked to a  phenyl residue para to its diazo linkage primarily to tyrosines in 
the protein  (28). In Pneumococcus, PC  substituents are phosphodiester linked to una- 
cetylated galactosamine residues in a repeat tetrasaccharide unit of C substance (29). 
The linkage of PC to cell wall constituents of P. morganii is not known, but because the 
composition of a Gram-negative cell well differs from a  Gram-positive cell wall and 
because P. morganii exhibits different reactivity with PC-BMP and antibodies (4,  16), 
we can infer that the structure of its PC-antigen is different. 
Each family of antibodies displays its own unique features and for that reason they 
will be considered separately. 
The T15 Family.  The various MP and HP of the T15 family all exhibit within the 
limits  of the  assay  system  the  same  fine  specificity,  even  though  we  know  from 
idiotypic and structural  studies  that  they differ in  their V  regions. That pattern is 
characterized by the position of PC and PC-Y as the best inhibitors of each hapten- 
carrier complex, PC-BGG, R36A,  and P. morganii. Analogues with substitutions  for 
the  phosphate  group or with  various chain  lengths  are  10-200  times less  effective 
based  on  molar concentrations at  I50. Thus,  when  the  phosphate  group  is  spaced 
further away from the TMA group, e.g., 3PPTMA, or replaced with another group 
(hydrophobic or ionic), binding is measurable but significantly weaker. These results 
suggest important binding site interactions between T15 antibodies and PC at both 
the trimethylammonium determinant and the phosphate determinant. This would be 
predicted by analogy to the crystal structure of M603 (30, 31). 
The fact that PC is the best inhibitor, regardless of the immunogen used to generate 
the  T15  HP,  indicates  that  interaction  with  the  PC  moiety  in  the  a25I-PC-BGG 
conjugate does not depend on the diazophenyl bridge or adjacent amino acids. This 
is supported by the activity of PC-Y, a  compound that  is always less effective than 
PC,  requiring  one  to  four  times  the  concentration  of PC  to  achieve comparable 
inhibition. Its structure has the same PC-phenyldiazo linkage that exists in PC-protein 
conjugates.  Furthermore,  the  fine specificity of all  T15  MP  and  HP  is  the  same 
regardless of whether they are tested against  PC-BGG, the pneumococcal, or, where 
possible, the proteus antigen. Thus, there exists a remarkable commonality in the T15 
binding sites for PC. Differences are seen only in the ability to bind P. morganii. Thus, 
carrier specificity is independent  of hapten specificity and  probably reflects amino 
acid substitutions in CDR positions that interact with moieties of the carrier. 
The M603 Family.  Like T15 HP, all M603 HP and MP (except HP116.5F3), have 
a characteristic fine specificity profile for the C analogues, but it is different from the 
T15  profile.  M603  HP  display  a  greater relative affinity for the  n--3  carboxylate 
derivative than  do T15  HP,  and  3COOH  along with  PC  and  PC-Y  are  the  best 
inhibitors. M603 HP have a low affinity for the nffi5 phenyl derivative in contrast to 
the  T15  family.  However,  these  HP  resemble  T15  HP  in  showing  the  strongest 
reactivity for PC, regardless of the origin of the HP or the ligand against which the 
fine specificity is measured. All the HP react with more than one carrier. A  special 1594  ANTI-PHOSPHOCHOLINE BINDING SITES 
feature of some M603 HP is their high activity for P. morganii, yet there is no apparent 
relationship between  hapten  and carrier specificity. Thus, just  like T15  HP, M603 
HP share  a  common hapten-binding  site but  they display different  reactivities for 
carrier determinants. 
HP116.5F3  is an exceptional HP. It has the greatest relative activity for PC-Y and 
binds PC 500-fold less well and no better than other analogues. Thus, the antibody 
displays  strong  anti-bridge  activity.  Sequence  analysis  of this  protein  will  prove 
extremely interesting because its L chain does not co-focus with M603 L chain, but it 
does contain the VH-PC Id that appears to identify the VH-4 isotype (32).  Does this 
antibody contain functionally important somatic mutations, different J  segments, or 
an unusual DH? Or is it encoded by different members of the VH-4 or VK-8 (M603L) 
gene family? 
The M511 Family.  Unlike T15 and M603 HP, the M511 antibodies exhibit extreme 
binding  site  diversity.  This  is  reflected  not  only  in  their  binding  to  the  hapten 
analogues but also in their level of reactivity for different PC-carrier complexes. For 
example, all bind PC-BGG about equally well, but they vary in their ability to bind 
R36A,  and  none  bind  P.  morganii significantly.  This  was  not  entirely  unexpected 
because we had previously shown  (5)  with  a  more limited  number of C  analogues 
that  binding  site diversity occurred  in  M511  HP.  Examination  of the  structure  of 
M511  and M167,  for which  complete H  and L  sequences are available, shows that 
these two proteins differ at multiple residues in H  chain CDR 2 and 3. Two in CDR 
2 are immediately adjacent to contact residues and one in CDR 3 at 100D is a contact 
residue for PC, at least in M603 Fab. Evaluation of these structural changes does not 
reveal a  simple explanation for the disparate specificity profiles of M 167 and M511. 
The  L  chains  of M511  and  M167  differ  in  six  positions  but  these  are  all  in  the 
framework (33,  34).  Because of the amount of structural  variability, more sequences 
will be required  before a  picture emerges. However, it seems probable that a  much 
greater degree of flexibility exists in the contour of the sites in various M511 antibodies 
than occurs in T15 and M603 HP. Model building exercises may permit a test of this 
hypothesis. 
Do the existing structural  data support  the concept of "fixed" site for PC  and a 
variable site for carrier? Two observations are pertinent.  First,  PC antigens exist in 
nature as the same hapten coupled to widely different carriers, i.e., microbial cell wall 
constituents.  Second,  the  site  for contact  with  PC-antigens,  at  least  in  the  X-ray 
diffraction model of M603, is a large surface of CDR residues on one end of the Fab 
that extends into the molecule, forming a  deep pocket  (30).  Thus, one could opera- 
tionally distinguish between the pocket that interacts with PC and the outer surfaces 
that might interact with carrier determinants. 
One could account for a fixed pocket by preservation of important charge interac- 
tions for PC. In fact, all anti-PC antibodies use a  VH-4 heavy chain  (34), and from 
analysis  of the  M603  X-ray structure  (30,  31),  it  is  clear  that  the  major  contact 
residues are found in the H  chain. They are located in the pocket at positions 33 and 
35 in CDR  1, positions 52 and 58 in CDR 2, and position  100 D  in CDR 3. They are 
the same in all T15 and M603 antibodies sequenced to date (6,  16) 2 as are adjacent 
regions  that  could  contribute  van  der  Waals  interactions  with  PC  and  aid  in 
maintaining a regular beta-pleated sheet structure (28). Those regions in the H  chain 
CDR displaying the greatest  variability can be excluded  as contact  residues for PC ANDRES ET AL.  1595 
but should be considered important in carrier reactivity. From the sequence data it is 
clear that the greatest variability in H  chains occurs in CDR 3, principally in the DH 
region. Other regions of significant but less extensive variability arise in the central 
portion of CDR  2.  Again, examination of the three-dimensional  model of M603  is 
revealing;  these  portions  of the CDR  2  and  3  would  be available to  interact  with 
carrier  determinants.  As  an  example,  M603  and  W3207  both  have the  same  fine 
specificity for the C analogues, yet they differ markedly in their binding ofP. morganii. 
All  the  contact  residues  for  PC  are  preserved  in  both  antibodies,  but  striking 
differences occur in DH and the central portion of CDR 2. 
How does one account for two different pockets for PC, one in Tl5 antibodies and 
another in M603 antibodies? Even without sequence data, one could suggest from the 
association of VK group with family that the L chain directly or indirectly determines 
the  nature  of the  fine  specificity pattern.  Preliminary  information  obtained  from 
heterologous H/L chain recombinants between H8, Tl5, M603, and W3207 support 
this hypothesis,  a Clear definition of its role in PC and carrier recognition, as well as 
defining the contribution  of CDR regions, will  require  more complete sequences of 
members in TI5 and M603  families. Additional  information should  also be gained 
from  chain  recombination  experiments  with  the  HP,  and  as  stated,  these  are  in 
progress. 
The genetic implications of a  conserved and a  variable component in an anti-PC 
site  are  intriguing.  Evolution  has  apparently  favored  development  of at  least  two 
common  and  fixed  pockets  for  PC.  The  need  for a  common  pocket  undoubtedly 
reflects the nature of PC-antigens in different environmental pathogens. Perhaps the 
ubiquitous distribution of PC in different organisms or the prevalence of certain PC- 
containing antigens led to the evolution of two important types of sites for PC. The 
high concentration of T15 Id  + anti-PC antibodies in normal serum (36)  and the high 
frequency of T 15 Id  + precursor B cells (9) support this hypothesis. Levels of M603 Id  + 
antibodies and precursors have not been measured in normal mice. However, these 
are the dominant antibodies after immunization with P. morganii (4). Variation on the 
theme (recognition of new or less common PC-containing microorganisms) could be 
accomplished  by  variation  in  those  binding  site  residues  interacting  with  carrier. 
Alternatively, the use of M51 I/M 167 OdK-24) L chains could permit accommodation 
of  infrequent  PC  antigens.  What  is  interesting  about  TI5  and  M603  anti-PC 
antibodies  is  that  variation  occurs  principally  in  carrier  recognition.  Functional 
variation may also be accomplished by somatic mutations in CDR, e.g., CDR  2 of 
M603 and W3207. 
We are currently testing these ideas in a  number of ways. Heterologous recombi- 
nation  experiments  among M603,  TI5,  and  M511  HP  of known  sequence  should 
allow us to determine not only the extent to which combinatorial association between 
families and among members of a  family contributes to diversity, but also to assess 
the  role  of L  chains  in  fine  specificity and  to  assign  a  role  for  DH.  We  are  also 
examining the binding of HP to PC antigens from a  variety of natural sources. This 
should shed light on the importance of a  fixed vs. a  variable site and hopefully allow 
us  to determine if DH length  or sequence or various somatic mutations  in  V  play 
significant roles in hapten or carrier recognition. 
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Summary 
The present investigation extends our immunochemical characterization of binding 
site  heterogeneity  among  a  large  series  of monoclonal  anti-phosphocholine  (PC) 
antibodies.  Hybridoma  proteins  (HP)  from  eight  genetically  distinct  strains  are 
included in this study, yet no strain specific characteristics were observed. These HP, 
as previously shown  (5), are divided into three well-defined families based on public 
or family-specific Id and L chain isotypes characteristic of three PC-binding myeloma 
proteins:  T15,  M603,  and  M511.  All  antibodies  exhibited  some degree of inter- or 
intra-family heterogeneity, or both. Some of this intra-family diversity was reflected 
by differential reactivity for PC when attached to three different carriers. In spite of 
this,  the  specificity  profiles  for  hapten  analogues  of PC,  as  measured  by  hapten 
inhibition of binding, were the same for all members of the T15 family. Altering the 
carrier had no effect, thus suggesting that the binding site pocket for PC is essentially 
preserved, whereas that for carrier is variable.  Similar conclusions were reached for 
most of the M603  HP, although the binding site is different from the T15 HP. The 
M511  HP stand in sharp contrast to the HP in the other two families because their 
binding sites exhibit extensive variability. The independence in reactivity for PC and 
PC plus carrier offers a  rational explanation  for idiotypic and/or structural  hetero- 
geneity  within  a  family.  More  importantly  it  suggests  interesting  strategies  for 
diversification within one group of antibodies. 
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